HomeBack to the synthesis

Screening list

Does one dose of psilocybin rewire the brain?

AI-assisted eligibility screening of 280 records under the linked, dated rules. Screened from titles and abstracts, with full-text passages where marked; human review is marked on each row. Inclusion means relevance, not support for lasting brain change. Exclusion means out of scope, not low quality. Records are not independent studies: several share participants. This is not a systematic review.

Direct (82)

Included and counted.

Direct works, 82 rows
WorkRuleBrain timingDosesFollow-upBasisReview
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder

Michael P. Bogenschutz, 2022

Randomised double-blind trial of two psilocybin doses plus psychotherapy for alcohol use disorder, reporting heavy drinking days over 32 weeks; clinical outcomes in patients.

Report an error

D2n/a232 weeks after first doseAbstract

Signed by Max Markovtsev, founder

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

Roland R. Griffiths, 2016

Randomized double-blind crossover trial of high versus very low dose psilocybin in 51 cancer patients, reporting depression and anxiety to 6 months.

Report an error

D2n/a26 monthsAbstract

Signed by Max Markovtsev, founder

Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels

Martin Korsbak Madsen, 2019

Report an error

D1During the drug1acute (same day)Abstract

Screened by AI

Psychedelics Promote Structural and Functional Neural Plasticity

Calvin Ly, 2018

Report an error

D3n/anonenot statedFull text

Checked by Astra, a second AI model

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

Alan K. Davis, 2020

Randomized waiting-list controlled trial of two psilocybin sessions in 27 adults with major depressive disorder, reporting depression at 1 and 4 weeks.

Report an error

D2n/a21 and 4 weeksAbstract

Signed by Max Markovtsev, founder

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

Robin Lester Carhart-Harris, 2012

Report an error

D1During the drugnot statedacuteAbstract

Screened by AI

Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors

Maxemiliano V. Vargas, 2023

Report an error

D3n/anonenot statedFull text

Checked by Astra, a second AI model

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

Robin Lester Carhart-Harris, 2016

Open-label trial of two psilocybin doses in treatment-resistant depression reporting depressive symptoms from one week to three months; a human trial with clinical outcomes.

Report an error

D2n/a23 monthsAbstract

Signed by Max Markovtsev, founder

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

Stephen Ross, 2016

Randomized placebo-controlled crossover trial of single-dose psilocybin versus niacin in 29 cancer patients, reporting anxiety and depression to 6.5 months.

Report an error

D2n/a17 weeks; 6.5 monthsAbstract

Signed by Max Markovtsev, founder

A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain

Nakul Ravi Raval, 2021

Report an error

D1After the acute effects11 day and 7 daysAbstract

Screened by AI

Emotions and brain function are altered up to one month after a single high dose of psilocybin

Frederick Streeter Barrett, 2020

Report an error

D1After the acute effects11 monthAbstract

Screened by AI

Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience

Martin Korsbak Madsen, 2021

Report an error

D1During the drug1acute (up to 5 hours)Abstract

Screened by AI

Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression

Matthew B. Wall, 2025

Report an error

D1After the acute effects23 weeksAbstract

Screened by AI

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up

Natalie Gukasyan, 2022

Report an error

D2n/a212 monthsAbstract

Screened by AI

Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice

Natalie Hesselgrave, 2021

Report an error

D1Not yet sorted1not statedAbstract

Screened by AI

Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals

Drummond E-Wen McCulloch, 2021

Report an error

D1After the acute effects11 week; 3 monthsAbstract

Checked by Astra, a second AI model

Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder

Manoj K. Doss, 2021

Report an error

D1After the acute effectsnot stated1 weekAbstract

Screened by AI

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

Robin Lester Carhart-Harris, 2017

Report an error

D2n/a26 monthsAbstract

Screened by AI

Different hierarchical reconfigurations in the brain by psilocybin and escitalopram for depression

Gustavo Deco, 2024

Report an error

D1After the acute effects23 weeks after second doseAbstract

Screened by AI

Dynamic coupling of whole-brain neuronal and neurotransmitter systems

Morten L. Kringelbach, 2020

Report an error

D1Not yet sortednot statednot statedAbstract

Screened by AI

Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression

Leor Roseman, 2017

Report an error

D1Not yet sorted21 dayAbstract

Screened by AI

Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer

Charles S. Grob, 2010

Report an error

D2n/a11, 3 and 6 monthsAbstract

Screened by AI

Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity

Débora Copa, 2024

Report an error

D2n/a2up to 24 weeksAbstract

Screened by AI

Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms

Robin Lester Carhart-Harris, 2017

Report an error

D1Not yet sortednot statednot statedAbstract

Screened by AI

Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity

Katrin H. Preller, 2020

Report an error

D1During the drug1acute (20 to 70 minutes)Abstract

Screened by AI

Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin

Joshua Daniel Rosenblat, 2024

Report an error

D2n/a1, 2 or 32 weeks (primary endpoint)Abstract

Checked by Astra, a second AI model

Psilocybin’s lasting action requires pyramidal cell types and 5-HT2A receptors

Ling-Xiao Shao, 2025

Report an error

D1During the drug1not statedAbstract

Screened by AI

Psychedelics promote plasticity by directly binding to BDNF receptor TrkB

Rafael Moliner, 2023

Report an error

D3n/anot statednot statedAbstract

Screened by AI

Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study

Luca Pellegrini, 2025

Report an error

D2n/a21 week; 4 weeksAbstract

Screened by AI

Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial

Robin von Rotz, 2022

Report an error

D2n/a114 daysAbstract

Screened by AI

The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers

Leor Roseman, 2014

Report an error

D1During the drugnot statedacuteAbstract

Screened by AI

Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression

Lea Julia Mertens, 2020

Report an error

D1After the acute effectsnot stated1 dayAbstract

Screened by AI

A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression

Brandon Weiss, 2023

Report an error

D2n/anot statednot statedAbstract

Screened by AI

Activation of Serotonin 2A Receptors Underlies the Psilocybin-Induced Effects on Oscillations, N170 Visual-Evoked Potentials, and Visual Hallucinations

Michael Kometer, 2013

Report an error

D1During the drugnot statedacuteAbstract

Screened by AI

Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice

Nicole Fadahunsi, 2022

Report an error

D1Not yet sorted1not statedAbstract

Screened by AI

Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression

Melissa Shukuroglou, 2022

Report an error

D1Not yet sorted21 dayAbstract

Screened by AI

Exploratory investigation of a patient‐informed low‐dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double‐blind, placebo‐controlled trial

Emmanuelle A. D. Schindler, 2022

Report an error

D2n/a33 to 8 weeks after first doseAbstract

Screened by AI

High-resolution tracking of unconfined zebrafish behavior reveals stimulatory and anxiolytic effects of psilocybin

Dotan Braun, 2024

Report an error

D1During the drugnot statedacuteAbstract

Screened by AI

Increased low-frequency brain responses to music after psilocybin therapy for depression

Matthew B. Wall, 2023

Report an error

D1After the acute effects21 dayAbstract

Screened by AI

Pilot study of psilocybin in patients with post-treatment lyme disease

Albert Garcia‐Romeu, 2026

Report an error

D2n/a21 month after second dose; 6 monthsAbstract

Screened by AI

Psilocybin facilitates fear extinction in mice by promoting hippocampal neuroplasticity

Yingjie Du, 2023

Report an error

D1Not yet sorted1not statedAbstract

Screened by AI

Psilocybin promotes neuroplasticity and induces rapid and sustained antidepressant-like effects in mice

Xiangting Zhao, 2024

Report an error

D1Not yet sorted1not statedAbstract

Screened by AI

Psychedelic 5-HT2A receptor agonism alters neurovascular coupling and differentially affects neuronal and hemodynamic measures of brain function

Jonah A. Padawer-Curry, 2025

Report an error

D1During the drugnot statedacuteAbstract

Screened by AI

Shared and Distinct Brain Regions Targeted for Immediate Early Gene Expression by Ketamine and Psilocybin

Pasha A. Davoudian, 2023

Report an error

D1During the drugnot statedacuteAbstract

Screened by AI

The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world

Rosalind Watts, 2022

Report an error

D2n/anot stated6 weeksAbstract

Screened by AI

UNRAVELing the synergistic effects of psilocybin and environment on brain-wide immediate early gene expression in mice

Daniel Ryskamp Rijsketic, 2023

Report an error

D1During the drugnot statednot statedAbstract

Screened by AI

A multi-institutional investigation of psilocybin’s effects on mouse behavior

Odilia Lu, 2026

Placed from the full text under rule D3: Mechanistic plasticity or critical-period study with a psilocybin or psilocin arm.

Report an error

D3n/a1Acute tests ~10 min after drug administration; persistent tests at least 24 h after drug administration, up to 4 d after drug administration for the corticosterone forced swim test; social reward adults pre-treated 4–5 d before the start of experiments, with the post-test on day 5Full text

Signed by Max Markovtsev, founder

Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression

Balázs Szigeti, 2024

Report an error

D2n/anot statednot statedAbstract

Screened by AI

Brain dynamics predictive of response to psilocybin for treatment-resistant depression

Jakub Vohryzek, 2024

Report an error

D2n/a2not statedAbstract

Screened by AI

Broadband Cortical Desynchronization Underlies the Human Psychedelic State

Suresh D Muthukumaraswamy, 2013

Report an error

D1During the drugnot statedacuteAbstract

Screened by AI

Classification of psychedelics and psychoactive drugs based on brain-wide imaging of cellular c-Fos expression

Farid Aboharb, 2025

Report an error

D1Not yet sortednot statednot statedAbstract

Screened by AI

Dose-dependent changes in global brain activity and functional connectivity following exposure to psilocybin: a BOLD MRI study in awake rats

Evan Fuini, 2025

Report an error

D1During the drugnot statedacuteAbstract

Screened by AI

Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin

Louis-David Lord, 2019

Report an error

D1During the drug1acuteAbstract

Screened by AI

Effects of psilocybin versus escitalopram on rumination and thought suppression in depression

Tommaso Barba, 2022

Report an error

D2n/anot stated6 weeks after treatment startAbstract

Screened by AI

Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studies

William Roseby, 2025

Report an error

D2n/anot statednot statedAbstract

Screened by AI

Evaluation of behavioural and neurochemical effects of psilocybin in mice subjected to chronic unpredictable mild stress

Ines Erkizia-Santamaría, 2025

Report an error

D1Not yet sorted2not statedAbstract

Screened by AI

From relaxed beliefs under psychedelics (REBUS) to revised beliefs after psychedelics (REBAS)

Richard J. Zeifman, 2025

Report an error

D1During the drug2acuteAbstract

Screened by AI

Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer

Gabrielle Agin-Liebes, 2020

Report an error

D2n/a13.2 and 4.5 yearsAbstract

Screened by AI

Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression – 12-month data from an open-label pilot study

Sara Ellis, 2025

Report an error

D2n/a112 monthsAbstract

Screened by AI

Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression

Brandon Weiss, 2023

Report an error

D2n/anot stated6 monthsAbstract

Screened by AI

Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder

Franklin R. Schneier, 2023

Report an error

D2n/a112 weeksAbstract

Screened by AI

Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial

Jacob S. Aday, 2025

Report an error

D2n/a21 monthAbstract

Screened by AI

Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication

Guy M. Goodwin, 2023

Report an error

D2n/a13 weeksAbstract

Screened by AI

Psilocybin restrains activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms

Kyna‐Anne Conn, 2024

Report an error

D1Not yet sortednot statednot statedAbstract

Screened by AI

Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic

Anthony L. Back, 2024

Report an error

D2n/a128 daysAbstract

Screened by AI

Psilocybin therapy for mood dysfunction in Parkinson’s disease: an open-label pilot trial

Ellen Bradley, 2025

Report an error

D2n/a21 month; 3 monthsAbstract

Screened by AI

Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial

Jordan Sloshower, 2023

Report an error

D2n/a1not-stated (16-week study)Abstract

Screened by AI

Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial

Nathalie M. Rieser, 2025

Report an error

D2n/a14 weeks and 6 monthsAbstract

Checked by Astra, a second AI model

Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study

Michael P. Bogenschutz, 2015

Report an error

D2n/a1 or 2not statedAbstract

Checked by Astra, a second AI model

Psychedelics align brain activity with context

Devon Stoliker, 2026

Report an error

D1During the drug1acute (about 80 to 150 minutes)Abstract

Screened by AI

Psychedelics and the ‘inner healer’: Myth or mechanism?

Joseph M. Peill, 2024

Report an error

D2n/a1not statedAbstract

Screened by AI

Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression

Leor Roseman, 2018

Report an error

D2n/a25 weeksAbstract

Screened by AI

Receptor-informed network control theory links LSD and psilocybin to a flattening of the brain’s control energy landscape

S. Parker Singleton, 2022

Report an error

D1During the drugnot statedacuteAbstract

Screened by AI

Sex-related differences in outcomes following psilocybin or escitalopram: a Bayesian secondary analysis

Aline Frick, 2026

Report an error

D2n/anot statednot statedAbstract

Screened by AI

Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life

Guy M. Goodwin, 2023

Report an error

D2n/a13 weeksAbstract

Screened by AI

Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial

Scott T. Aaronson, 2025

Report an error

D2n/a13 weeks and 12 weeksAbstract

Screened by AI

Single-dose psilocybin rapidly and sustainably relieves allodynia and anxiodepressive-like behaviors in mouse models of chronic pain

Ahmad Hammo, 2025

Report an error

D1Not yet sorted1not statedAbstract

Screened by AI

Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes

Scott T. Aaronson, 2023

Report an error

D2n/a13 weeks; 12 weeksAbstract

Screened by AI

The hidden therapist: evidence for a central role of music in psychedelic therapy

Mendel Kaelen, 2018

Report an error

D2n/anot stated1 weekAbstract

Screened by AI

The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression

Guy M. Goodwin, 2024

Report an error

D2n/a13 weeksAbstract

Screened by AI

The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder

Adam W. Levin, 2024

Report an error

D2n/a24 weeks to 12 monthsAbstract

Screened by AI

The unique neural signature of your trip: Functional connectome fingerprints of subjective psilocybin experience

Hanna M. Tolle, 2023

Report an error

D1During the drugnot statedacuteAbstract

Screened by AI

Indirect (21)

Included and counted, labelled as indirect.

Indirect works, 21 rows
WorkRuleBrain timingDosesFollow-upBasisReview
5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines

Lindsay P. Cameron, 2023

Report an error

I1n/a1sucrose preference 24 hours after the psilocybin doseFull text

Checked by Astra, a second AI model

Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice

Mario de la Fuente Revenga, 2021

Report an error

I4n/anonedaysAbstract

Checked by Astra, a second AI model

Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action

Franz X. Vollenweider, 1998

Report an error

I3n/anot statedacuteAbstract

Screened by AI

Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats

Kat F. Kiilerich, 2023

Report an error

I6n/arepeatednot statedAbstract

Screened by AI

Serotonin 5-HT2A, 5-HT2c and 5-HT1A receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response

Ines Erkizia-Santamaría, 2022

Report an error

I3n/anot statedacuteAbstract

Screened by AI

Subacute effects of the psychedelic ayahuasca on the salience and default mode networks

Lorenzo Pasquini, 2020

Report an error

I4n/anone24 hoursAbstract

Screened by AI

5-HT2AReceptor-Mediated Regulation of Brain-Derived Neurotrophic Factor mRNA in the Hippocampus and the Neocortex

Vidita A. Vaidya, 1997

Report an error

I4n/anonenot statedAbstract

Screened by AI

Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player?

Mehdi Sekssaoui, 2024

Report an error

I1n/a115 daysAbstract

Screened by AI

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

Roland R. Griffiths, 2006

Report an error

I2n/a12 monthsAbstract

Screened by AI

Psilocybin Facilitates Fear Extinction: Importance of Dose, Context, and Serotonin Receptors

Samuel C. Woodburn, 2024

Report an error

I1n/anot statednot statedAbstract

Screened by AI

Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression

Meghan Hibicke, 2020

Report an error

I1n/a1not statedAbstract

Screened by AI

5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice

Sarah J. Jefferson, 2023

Report an error

I4n/anot statednot statedAbstract

Screened by AI

A Single Dose of Lysergic Acid Diethylamide Influences Gene Expression Patterns within the Mammalian Brain

Charles David Nichols, 2002

Report an error

I4n/anoneacuteAbstract

Screened by AI

Acute anxiogenic effects of psilocybin and the related tryptamine, norbaeocystin, in male and female rats

Marisa J. Savini, 2026

Report an error

I1n/anot stated24 hoursAbstract

Screened by AI

Acute psilocybin enhances cognitive flexibility in rats

Alejandro Torrado Pacheco, 2023

Report an error

I3n/anot statedacuteAbstract

Screened by AI

Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants

A. Becker, 2022

Report an error

I4n/anoneacuteAbstract

Screened by AI

Lysergic acid diethylamide pretreatment prolongs brain-stimulation induced neural activity changes

Lucas L. Dwiel, 2026

Report an error

I4n/anoneLSD given 24 hours before cortical stimulation; neural activity changes followed over minutes to days after stimulationAbstract

Checked by Astra, a second AI model

Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later

R. R. Griffiths, 2008

Report an error

I2n/a114 monthsAbstract

Screened by AI

Rapid antidepressant-like effect of non-hallucinogenic psychedelic analog lisuride, but not hallucinogenic psychedelic DOI, in lipopolysaccharide-treated mice

Youge Qu, 2022

Report an error

I4n/anonenot statedAbstract

Screened by AI

Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice

Mario de la Fuente Revenga, 2022

Report an error

I4n/anone24 hoursAbstract

Screened by AI

Vigilance state dissociation induced by 5-MeO-DMT in mice

Benjamin J. B. Bréant, 2026

Report an error

I4n/anonesleep recorded over the 48 hours after dosingAbstract

Checked by Astra, a second AI model

Pending (2)

Not yet decided.

Pending works, 2 rows
WorkRuleBrain timingDosesFollow-upBasisReview
Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior

Javier González‐Maeso, 2007

Eligibility remains unresolved. Next try 16 November 2026.

Report an error

Pn/anot statednot statedAbstract

Screened by AI

Must Psilocybin Always “Assist Psychotherapy”?

Guy M. Goodwin, 2023

Eligibility remains unresolved. Next try 16 November 2026.

Report an error

Pn/anot statednot statedTitle only

Screened by AI

Context (100)

Listed, not counted. Reviews, commentaries and other works without original data.

Context works, 100 rows
WorkRuleBrain timingDosesFollow-upBasisReview
Canalization and plasticity in psychopathology

Robin Lester Carhart-Harris, 2022

Report an error

Cn/anonen/aAbstract

Screened by AI

Psychedelics

David E. Nichols, 2016

Report an error

Cn/anonen/aAbstract

Screened by AI

REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics

Robin Lester Carhart-Harris, 2019

Report an error

Cn/anonen/aAbstract

Screened by AI

Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis

Yuan Yao, 2024

Report an error

Cn/anonen/aAbstract

Screened by AI

Neurocognitive effects of psilocybin: A systematic and comprehensive review of neuroimaging studies in humans

Lucie Berkovitch, 2025

Report an error

Cn/anonen/aAbstract

Screened by AI

Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses

Drummond E-Wen McCulloch, 2022

Report an error

Cn/anonen/aAbstract

Screened by AI

Serotonin 2A Receptor (5-HT 2A R) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants

Wenwen Duan, 2023

Report an error

Cn/anonen/aAbstract

Screened by AI

Structural neural plasticity evoked by rapid-acting antidepressant interventions

Clara Liao, 2024

Report an error

Cn/anonen/aAbstract

Screened by AI

The science of psychedelic medicine

Joshua S. Siegel, 2026

Report an error

Cn/anonen/aAbstract

Screened by AI

A neurophenomenological approach to non-ordinary states of consciousness: hypnosis, meditation, and psychedelics

Christopher Timmermann, 2022

Report an error

Cn/anonen/aAbstract

Screened by AI

Expectancy Effects in Psychedelic Trials

Balázs Szigeti, 2024

Report an error

Cn/anonen/aAbstract

Screened by AI

Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics

Alaina M. Jaster, 2023

Report an error

Cn/anonen/aAbstract

Screened by AI

Multilevel Mechanisms and Clinical Efficacy of Psilocybin in Depression Treatment: A Systematic Review

Xizhen Zhang, 2026

Report an error

Cn/anonen/aAbstract

Screened by AI

Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders

Franz X. Vollenweider, 2020

Report an error

Cn/anonen/aAbstract

Screened by AI

Psychedelic-Induced Neural Plasticity: A Comprehensive Review and a Discussion of Clinical Implications

Francesco Weiss, 2025

Report an error

Cn/anonen/aAbstract

Screened by AI

Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile

Friederike Holze, 2024

Report an error

Cn/anonen/aAbstract

Screened by AI

The intensity of the psychedelic experience is reliably associated with clinical improvements: A systematic review and meta-analysis

Bruno Roméo, 2025

Report an error

Cn/anonen/aAbstract

Screened by AI

The neural basis of psychedelic action

Alex C. Kwan, 2022

Report an error

Cn/anonen/aAbstract

Screened by AI

Therapeutic mechanisms of psychedelics and entactogens

Boris Dov Heifets, 2023

Report an error

Cn/anonen/aAbstract

Screened by AI

A Dendrite-Focused Framework for Understanding the Actions of Ketamine and Psychedelics

Neil K. Savalia, 2020

Report an error

Cn/anonen/aAbstract

Screened by AI

Acute Adverse Effects of Therapeutic Doses of Psilocybin

Akhila Yerubandi, 2024

Report an error

Cn/anonen/aAbstract

Screened by AI

Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression

Johannes Gerardus Ramaekers, 2025

Report an error

Cn/anonen/aAbstract

Screened by AI

Beyond the 5-HT2AReceptor: Classic and Nonclassic Targets in Psychedelic Drug Action

Lindsay P. Cameron, 2023

Report an error

Cn/anonen/aAbstract

Screened by AI

Beyond the serotonin deficit hypothesis: communicating a neuroplasticity framework of major depressive disorder

Chloe E. Page, 2024

Report an error

Cn/anonen/aAbstract

Screened by AI

Current status and future prospects of research on psilocybin's regulation of neurotransmitters and their receptors related to the pathogenesis of tinnitus

Shuhan Lu, 2026

Report an error

Cn/anonen/aAbstract

Screened by AI

Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis

Athina-Marina Metaxa, 2024

Report an error

Cn/anonen/aAbstract

Screened by AI

History repeating: guidelines to address common problems in psychedelic science

Michiel van Elk, 2023

Report an error

Cn/anonen/aAbstract

Screened by AI

Human hallucinogen research: guidelines for safety

MW Johnson, 2008

Report an error

Cn/anonen/aAbstract

Screened by AI

Immune-brain plasticity underpins stress and affective behaviors

Jinsu Lee, 2025

Report an error

Cn/anonen/aAbstract

Screened by AI

Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression

Susan Ling, 2021

Report an error

Cn/anonen/aAbstract

Screened by AI

Neuroimaging in psychedelic drug development: past, present, and future

Matthew B. Wall, 2023

Report an error

Cn/anonen/aAbstract

Screened by AI

Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review

Michiel van Elk, 2022

Report an error

Cn/anonen/aAbstract

Screened by AI

Potential Differences in Psychedelic Actions Based on Biological Sex

Sheida Shadani, 2024

Report an error

Cn/anonen/aAbstract

Screened by AI

Preparing for the Bursting of the Psychedelic Hype Bubble

David B. Yaden, 2022

Report an error

Cn/anonen/aAbstract

Screened by AI

Psilocybin for the treatment of Alzheimer’s disease

Siyi Zheng, 2024

Report an error

Cn/anonen/aAbstract

Screened by AI

Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies

Natacha Perez, 2023

Report an error

Cn/anonen/aAbstract

Screened by AI

Psilocybin-assisted therapy for depression: A systematic review and meta-analysis

Sipan Haikazian, 2023

Report an error

Cn/anonen/aAbstract

Screened by AI

Psychedelic medicine: mechanisms, evidence, and translation to practice

Edward Jacobs, 2026

Report an error

Cn/anonen/aAbstract

Screened by AI

Psychedelic Psychiatry’s Brave New World

David Nutt, 2020

Report an error

Cn/anonen/aAbstract

Screened by AI

Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis

Kwonmok Ko, 2022

Report an error

Cn/anonen/aAbstract

Screened by AI

Psychedelics

Benjamin Kelmendi, 2022

Report an error

Cn/anonen/aAbstract

Screened by AI

Psychedelics and the essential importance of context

Robin Lester Carhart-Harris, 2018

Report an error

Cn/anonen/aAbstract

Screened by AI

Safety and risk assessment of psychedelic psychotherapy: A meta-analysis and systematic review

Bruno Roméo, 2024

Report an error

Cn/anonen/aAbstract

Screened by AI

Serotonin and brain function: a tale of two receptors

Robin Lester Carhart-Harris, 2017

Report an error

Cn/anonen/aAbstract

Screened by AI

Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology

Kenneth Shinozuka, 2024

Report an error

Cn/anonen/aAbstract

Screened by AI

The entropic brain today

Robin Lester Carhart-Harris, 2026

Report an error

Cn/anonen/aAbstract

Screened by AI

The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs

Robin Lester Carhart-Harris, 2014

Report an error

Cn/anonen/aAbstract

Screened by AI

The pharmacology of psilocybin

Torsten Passie, 2002

Report an error

Cn/anonen/aAbstract

Screened by AI

The promises and perils of psychedelic pharmacology for psychiatry

Tristan D. McClure‐Begley, 2022

Report an error

Cn/anonen/aAbstract

Screened by AI

The Therapeutic Potential of Psilocybin

Henry I. C. Lowe, 2021

Report an error

Cn/anonen/aAbstract

Screened by AI

Towards an understanding of psychedelic-induced neuroplasticity

Abigail E. Calder, 2022

Report an error

Cn/anonen/aAbstract

Screened by AI

A complex systems perspective on psychedelic brain action

Manesh Girn, 2023

Report an error

Cn/anonen/aAbstract

Screened by AI

Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review

Joost J. Breeksema, 2022

Report an error

Cn/anonen/aAbstract

Screened by AI

Are “mystical experiences” essential for antidepressant actions of ketamine and the classic psychedelics?

Kenji Hashimoto, 2024

Report an error

Cn/anonen/aAbstract

Screened by AI

Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity

David E. Olson, 2022

Report an error

Cn/anonen/aAbstract

Screened by AI

Clinical and preclinical evidence of psilocybin as antidepressant. A narrative review

Ines Erkizia-Santamaría, 2025

Report an error

Cn/anonen/aAbstract

Screened by AI

Clinically relevant acute subjective effects of psychedelics beyond mystical experience

David B. Yaden, 2024

Report an error

Cn/anonen/aTitle only

Screened by AI

Cross-species mapping of acute psychedelic-responsive genes links HTR2A cortical expression, cell-type enrichment, and human cortical expression modules

Patrick A. McConnell, 2026

Report an error

Cn/anonen/aAbstract

Screened by AI

Default Mode Network Modulation by Psychedelics: A Systematic Review

James J Gattuso, 2022

Report an error

Cn/anonen/aAbstract

Screened by AI

Emerging mechanisms of psilocybin-induced neuroplasticity

Sonia Sonda, 2025

Report an error

Cn/anonen/aAbstract

Screened by AI

Emerging Medications for Treatment-Resistant Depression: A Review with Perspective on Mechanisms and Challenges

Michael J. Lucido, 2025

Report an error

Cn/anonen/aAbstract

Screened by AI

Ethnoracial inclusion in clinical trials of psychedelics: a systematic review

Marcus E. Hughes, 2024

Report an error

Cn/anonen/aAbstract

Screened by AI

Hallucinogens

David E. Nichols, 2004

Report an error

Cn/anonen/aAbstract

Screened by AI

How Psychedelics Modulate Multiple Memory Mechanisms in Posttraumatic Stress Disorder

Manoj K. Doss, 2024

Report an error

Cn/anonen/aAbstract

Screened by AI

Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment

Jenessa N. Johnston, 2023

Report an error

Cn/anonen/aAbstract

Screened by AI

Lower-dose psycholytic therapy – A neglected approach

Torsten Passie, 2022

Report an error

Cn/anonen/aAbstract

Screened by AI

Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants

Tao Chen, 2023

Report an error

Cn/anonen/aAbstract

Screened by AI

Neuroplasticity and psychedelics: A comprehensive examination of classic and non-classic compounds in pre and clinical models

Claudio Agnorelli, 2025

Report an error

Cn/anonen/aAbstract

Screened by AI

On the meaning of “plasticity” in neuroscience and mental health research and its relation to the action of psychedelic therapy

Robin Lester Carhart-Harris, 2026

Report an error

Cn/anonen/aAbstract

Screened by AI

Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape

Manish K. Jha, 2023

Report an error

Cn/anonen/aAbstract

Screened by AI

Psilocybin and Hallucinogenic Mushrooms

Mathieu Fradet, 2024

Placed from the full text under rule C: Context contains reviews, meta-analyses, commentaries, editorials, viewpoints, protocols, conference abstracts without data, and books or chapters without original data that discuss psilocybin, other serotonergic psychedelics, or interpretation of brain measurements under psychedelics.

Report an error

Cn/anot statedNot stated for any brain measure. A cited imaging study's anterior hippocampus decrease lasted at least 3 weeks, with no reference dose named.Full text

Signed by Max Markovtsev, founder

Psilocybin for major depressive disorder: a systematic review of randomized controlled studies

Lijuan Li, 2024

Report an error

Cn/anonen/aAbstract

Screened by AI

Psilocybin in late-life mental health: Addressing depression, loneliness, and existential anxiety

Gerasimos Konstantinou, 2025

Report an error

Cn/anonen/aAbstract

Screened by AI

Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy

Seetal Dodd, 2022

Report an error

Cn/anonen/aAbstract

Screened by AI

Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism

Jennifer Mitchell, 2023

Report an error

Cn/anonen/aAbstract

Screened by AI

Psychedelic Therapy vs Antidepressants for the Treatment of Depression Under Equal Unblinding Conditions

Zachary J. Williams, 2026

Report an error

Cn/anonen/aAbstract

Screened by AI

Psychedelic-assisted psychotherapy: where is the psychotherapy research?

Jacob S. Aday, 2024

Report an error

Cn/anonen/aAbstract

Screened by AI

Psychedelics and Other Psychoplastogens for Treating Mental Illness

Maxemiliano V. Vargas, 2021

Report an error

Cn/anonen/aAbstract

Screened by AI

Psychedelics as Transformative Therapeutics

Bryan L. Roth, 2023

Report an error

Cn/anonen/aAbstract

Screened by AI

Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential

Josh Allen, 2024

Report an error

Cn/anonen/aAbstract

Screened by AI

Psychedelics therapeutics: What we know, what we think, and what we need to research

David Nutt, 2022

Report an error

Cn/anonen/aAbstract

Screened by AI

Randomized Controlled Trials of Psilocybin‐Assisted Therapy in the Treatment of Major Depressive Disorder: Systematic Review and Meta‐Analysis

Vikas Menon, 2024

Report an error

Cn/anonen/aAbstract

Screened by AI

Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review

Oliver Rumle Hovmand, 2023

Report an error

Cn/anonen/aAbstract

Screened by AI

Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action?

Muhammad Ishrat Husain, 2023

Report an error

Cn/anonen/aAbstract

Screened by AI

Serotonin biology as a basis for explaining psychedelic drug action

Cory A. Knox, 2026

Report an error

Cn/anonen/aFetched abstract

Screened by AI

Study Protocol for “Exploring the safety and therapeutic potential of psilocybin in the treatment of anorexia nervosa in adolescents and young adults”

David K. Sjöström, 2026

Report an error

Cn/a2n/aAbstract

Screened by AI

Studying Harms Is Key to Improving Psychedelic-Assisted Therapy—Participants Call for Changes to Research Landscape

Sarah McNamee, 2023

Report an error

Cn/anonen/aAbstract

Screened by AI

Synaptic priming: A framework for pharmacotherapy in depression

Kyle A. Brown, 2025

Report an error

Cn/anonen/aAbstract

Screened by AI

Targeting metaplasticity mechanisms to promote sustained antidepressant actions

Kyle A. Brown, 2024

Report an error

Cn/anonen/aAbstract

Screened by AI

The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology

Andrea Mastinu, 2023

Report an error

Cn/anonen/aAbstract

Screened by AI

The effect of psilocybin on empathy and prosocial behavior: a proposed mechanism for enduring antidepressant effects

Kush V. Bhatt, 2024

Report an error

Cn/anonen/aAbstract

Screened by AI

The mechanistic divide in psychedelic neuroscience: An unbridgeable gap?

Bryan R. Barksdale, 2024

Report an error

Cn/anonen/aAbstract

Screened by AI

The Psychedelic Future of Post-Traumatic Stress Disorder Treatment

Tamar Glatman Zaretsky, 2024

Report an error

Cn/anonen/aAbstract

Screened by AI

The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects

David B. Yaden, 2020

Report an error

Cn/anonen/aAbstract

Screened by AI

The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects

David E. Olson, 2020

Report an error

Cn/anonen/aAbstract

Screened by AI

The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future

Robin Lester Carhart-Harris, 2017

Report an error

Cn/anonen/aAbstract

Screened by AI

Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies

Kristoffer Andreas Aamodt Andersen, 2020

Report an error

Cn/anonen/aAbstract

Screened by AI

Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money

Keith N. Humphreys, 2024

Report an error

Cn/anonen/aAbstract

Screened by AI

Treatment with psychedelics is psychotherapy: beyond reductionism

Gerhard Gründer, 2023

Report an error

Cn/anonen/aAbstract

Screened by AI

What fMRI studies say about the nature of the psychedelic effect: a scoping review

Michal Beneš, 2025

Report an error

Cn/anonen/aAbstract

Screened by AI

Excluded (75)

Out of scope, not counted.

Excluded works, 75 rows
WorkRuleBrain timingDosesFollow-upBasisReview
Neural correlates of the LSD experience revealed by multimodal neuroimaging

Robin Lester Carhart-Harris, 2016

Report an error

X1n/anonen/aAbstract

Screened by AI

A non-hallucinogenic psychedelic analogue with therapeutic potential

Lindsay P. Cameron, 2020

Report an error

X1n/anonen/aAbstract

Screened by AI

Human brain effects of DMT assessed via EEG-fMRI

Christopher Timmermann, 2023

Report an error

X1n/anonen/aAbstract

Screened by AI

The organization of the human cerebral cortex estimated by intrinsic functional connectivity

B.T. Thomas Yeo, 2011

Report an error

X3n/anonen/aAbstract

Screened by AI

The polypharmacology of psychedelics reveals multiple targets for potential therapeutics

Manish Kumar Jain, 2025

Report an error

X2n/anonen/aAbstract

Screened by AI

A component based noise correction method (CompCor) for BOLD and perfusion based fMRI

Yashar Behzadi, 2007

Report an error

X3n/anonen/aAbstract

Screened by AI

A High-ResolutionIn VivoAtlas of the Human Brain's Serotonin System

Vincent Beliveau, 2016

Report an error

X3n/anonen/aAbstract

Screened by AI

Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity

Anat Levit Kaplan, 2022

Report an error

X1n/anonen/aAbstract

Screened by AI

Edible and Medicinal Fungi as Candidate Natural Antidepressants: Mechanisms and Nutritional Implications

Pin Gong, 2025

Report an error

X1n/anonen/aAbstract

Screened by AI

Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory

Leor Roseman, 2019

Report an error

X3n/anot statedn/aAbstract

Screened by AI

From Stress to Synapse: The Neuronal Atrophy Pathway to Mood Dysregulation

Henry Krasner, 2025

Report an error

X1n/anonen/aAbstract

Checked by Astra, a second AI model

Isolation of psychedelic-responsive neurons underlying anxiolytic behavioral states

Jessie Muir, 2024

Report an error

X1n/anonenot statedFull text

Checked by Astra, a second AI model

Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments

John Harrison Krystal, 2023

Report an error

X1n/anonen/aAbstract

Screened by AI

Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine

Mihai Avram, 2024

Report an error

X1n/anonen/aAbstract

Screened by AI

Longitudinal Effects of Ketamine on Dendritic Architecture In Vivo in the Mouse Medial Frontal Cortex

Victoria Phoumthipphavong, 2016

Report an error

X1n/anonen/aAbstract

Screened by AI

New and emerging approaches to treat psychiatric disorders

Katherine Wilson Scangos, 2023

Report an error

X3n/anonen/aAbstract

Checked by Astra, a second AI model

Novel and emerging treatments for major depression

Steven Marwaha, 2022

Report an error

X1n/anonen/aAbstract

Checked by Astra, a second AI model

Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation

R. N. Moda-Sava, 2019

Report an error

X1n/anonen/aAbstract

Screened by AI

The Psychedelic State Induced by Ayahuasca Modulates the Activity and Connectivity of the Default Mode Network

Fernanda Palhano-Fontes, 2015

Report an error

X1n/anonen/aAbstract

Screened by AI

A framework for assessment of adverse events occurring in psychedelic-assisted therapies

Roman Palitsky, 2024

Report an error

X3n/anonen/aAbstract

Screened by AI

A New Depression Scale Designed to be Sensitive to Change

Stuart Montgomery, 1979

Report an error

X3n/anonen/aAbstract

Screened by AI

Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor

Katrin H. Preller, 2018

Report an error

X1n/anoneacuteAbstract

Screened by AI

Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis

Andrea Cipriani, 2018

Report an error

X1n/anonen/aAbstract

Screened by AI

Cortical Surface-Based Analysis

Anders Martin Dale, 1999

Report an error

X3n/anonen/aAbstract

Screened by AI

Defining ‘psychedelic’

Avery E. Ostrand, 2026

Report an error

X2n/anonen/aAbstract

Screened by AI

Depression, Stress, and Anhedonia: Toward a Synthesis and Integrated Model

Diego A. Pizzagalli, 2014

Report an error

X3n/anonen/aAbstract

Screened by AI

Depressive Rumination, the Default-Mode Network, and the Dark Matter of Clinical Neuroscience

J. Paul Hamilton, 2015

Report an error

X3n/anonen/aAbstract

Checked by Astra, a second AI model

Differences across sexes on head-twitch behavior and 5-HT2A receptor signaling in C57BL/6J mice

Alaina M. Jaster, 2022

Report an error

X1n/anonen/aAbstract

Screened by AI

Dynamic mapping of human cortical development during childhood through early adulthood

Nitin Gogtay, 2004

Report an error

X3n/anonen/aAbstract

Screened by AI

Effects of inhaled cannabis high in Δ9-THC or CBD on the aging brain: A translational MRI and behavioral study

Aymen H. Sadaka, 2023

Report an error

X1n/anonen/aAbstract

Screened by AI

Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI)

Matthew M. Nour, 2016

Report an error

X3n/anot statedn/aAbstract

Screened by AI

Eigenmodes of the deep unconscious: the neuropsychology of Jungian archetypes and psychedelic experience

Hugh T. McGovern, 2025

Report an error

X3n/anonen/aAbstract

Screened by AI

Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses?

Adam Opbroek, 2002

Report an error

X1n/anonen/aAbstract

Screened by AI

Essentials of Informed Consent to Psychedelic Medicine

Mason Marks, 2024

Report an error

X2n/anonen/aAbstract

Screened by AI

Expert recommendations for Germany’s integration of psychedelic-assisted therapy

Sergio Pérez Rosal, 2024

Report an error

X2n/anonen/aAbstract

Screened by AI

Extended difficulties following the use of psychedelic drugs: A mixed methods study

Jules Evans, 2023

Report an error

X2n/anot statednot statedAbstract

Screened by AI

Functional neuroimaging in psychiatry and the case for failing better

Matthew M. Nour, 2022

Report an error

X3n/anonen/aAbstract

Checked by Astra, a second AI model

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

Arnold, Marcel, 2018

Report an error

X3n/anonen/aTitle only

Screened by AI

Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey

Emmanuelle A. D. Schindler, 2015

Report an error

X2n/anot statedn/aAbstract

Screened by AI

Ketamine disinhibits dendrites and enhances calcium signals in prefrontal dendritic spines

Farhan Ali, 2020

Report an error

X1n/anonen/aAbstract

Screened by AI

Local-Global Parcellation of the Human Cerebral Cortex from Intrinsic Functional Connectivity MRI

Alexander Schaefer, 2017

Report an error

X3n/anonen/aAbstract

Screened by AI

Lower synaptic density is associated with depression severity and network alterations

Sophie E. Holmes, 2019

Report an error

X3n/anonen/aAbstract

Screened by AI

LSD alters dynamic integration and segregation in the human brain

Andrea I. Luppi, 2020

Report an error

X1n/anonen/aAbstract

Screened by AI

LSD‐induced entropic brain activity predicts subsequent personality change

Alexander V. Lebedev, 2016

Report an error

X1n/anoneacuteAbstract

Screened by AI

LSD, afterglow and hangover: Increased episodic memory and verbal fluency, decreased cognitive flexibility

Isabel Wießner, 2022

Report an error

X1n/anonen/aAbstract

Screened by AI

Lysergic acid diethylamide induces increased signalling entropy in rats’ prefrontal cortex

Aurora Savino, 2021

Report an error

X1n/anonen/aAbstract

Screened by AI

Magnesium–ibogaine therapy effects on cortical oscillations and neural complexity in veterans with traumatic brain injury

Jennifer I. Lissemore, 2025

Report an error

X1n/anonen/aTitle only

Screened by AI

MDMA and MDMA-Assisted Therapy

Aaron S. Wolfgang, 2025

Report an error

X1n/anonen/aAbstract

Screened by AI

Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential

Jeremy R. Tuck, 2025

Report an error

X1n/anonen/aAbstract

Screened by AI

mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

Nanxin Li, 2010

Report an error

X1n/anonen/aAbstract

Screened by AI

Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey

Sandeep Manel Nayak, 2023

Report an error

X2n/a12-3 monthsAbstract

Screened by AI

Neural complexity is increased after low doses of LSD, but not moderate to high doses of oral THC or methamphetamine

Conor H. Murray, 2024

Report an error

X1n/anoneacuteAbstract

Screened by AI

Neural correlates of the DMT experience assessed with multivariate EEG

Christopher Timmermann, 2019

Report an error

X1n/anonen/aAbstract

Screened by AI

NIH Image to ImageJ: 25 years of image analysis

Caroline A Schneider, 2012

Report an error

X3n/anonen/aAbstract

Screened by AI

Nipype: A Flexible, Lightweight and Extensible Neuroimaging Data Processing Framework in Python

Krzysztof J. Gorgolewski, 2011

Report an error

X3n/anonen/aAbstract

Screened by AI

Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study

Joost J. Breeksema, 2024

Report an error

X2n/a1not statedAbstract

Screened by AI

Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants

Friederike Holze, 2022

Report an error

X2n/anot statedn/aAbstract

Screened by AI

Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy- N,N -dimethyltryptamine benzoate) in healthy participants

James Rucker, 2024

Report an error

X1n/anonen/aAbstract

Screened by AI

Prospective examination of the therapeutic role of psychological flexibility and cognitive reappraisal in the ceremonial use of ayahuasca

Gabrielle Agin-Liebes, 2022

Report an error

X1n/anonen/aAbstract

Screened by AI

Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV)

Erich Studerus, 2010

Report an error

X3n/anot statedn/aAbstract

Screened by AI

Rapid Precision Functional Mapping of Individuals Using Multi-Echo fMRI

Charles J. Lynch, 2020

Report an error

X3n/anonen/aAbstract

Screened by AI

Relapse rates after psychotherapy for depression – stable long-term effects? A meta-analysis

Christiane Steinert, 2014

Report an error

X3n/anonen/aAbstract

Screened by AI

Response of cluster headache to psilocybin and LSD

Richard Andrew Sewell, 2006

Report an error

X2n/anot statedn/aAbstract

Screened by AI

Serotonin Induces Excitatory Postsynaptic Potentials in Apical Dendrites of Neocortical Pyramidal Cells

George K. Aghajanian, 1997

Report an error

X1n/anonen/aAbstract

Screened by AI

Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder

Reid J. Robison, 2025

Report an error

X1n/anonen/aAbstract

Screened by AI

Structural pharmacology and therapeutic potential of 5-methoxytryptamines

Audrey L. Warren, 2024

Report an error

X1n/anonen/aAbstract

Screened by AI

Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor

Kuglae Kim, 2020

Report an error

X1n/anonen/aAbstract

Screened by AI

Synaptic Mechanisms Regulating Mood State Transitions in Depression

Puja K. Parekh, 2022

Report an error

X1n/anonen/aAbstract

Checked by Astra, a second AI model

The Aversive Lens: Stress effects on the prefrontal-cingulate cortical pathways that regulate emotion

Amy F.T. Arnsten, 2022

Report an error

X1n/anonen/aAbstract

Checked by Astra, a second AI model

The Digital Twin Brain: A Bridge between Biological and Artificial Intelligence

Hui Xiong, 2023

Report an error

X3n/anonen/aAbstract

Screened by AI

The Hallucinogen DOI Reduces Low-Frequency Oscillations in Rat Prefrontal Cortex: Reversal by Antipsychotic Drugs

Pau Celada, 2008

Report an error

X1n/anonen/aAbstract

Screened by AI

The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10

David V. Sheehan, 1998

Report an error

X3n/anonen/aTitle only

Screened by AI

Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions

Roger S. McIntyre, 2023

Report an error

X1n/anonen/aAbstract

Checked by Astra, a second AI model

Using the rat forced swim test to assess antidepressant-like activity in rodents

David Anthony Slattery, 2012

Report an error

X3n/anonen/aAbstract

Screened by AI

Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience

Joseph M. Peill, 2022

Report an error

X3n/anot statedn/aAbstract

Screened by AI

PsychDoc is a division of Violema, Inc.

© 2026 Violema, Inc.